External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

SeaStar Medical Holding  / Equity Bottom-Up

Key points (machine generated)<ul><li>SeaStar Medical is developing the Selective Cytopheretic Device (SCD) to treat critically ill patients with hyperinflammation.</li><li>The SCD has received FDA approval for pediatric acute kidney injury and is expected to generate interim data from its adult trial by late Q3 next year.</li><li>The company currently has $10 million in cash but may need to raise additional funds for growth and to support its adult trial.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)SeaStar Medical is developing the Selective Cytopheretic Device (SCD) to treat critically ill patients with hyperinflammation.The SCD has received FDA approval for pediatric acute kidney injury and is expected to generate interim data from its adult trial by late Q3 next year.The company currently has $10 million in cash but may need to raise additional funds for growth and to support its adult trial.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Seastar Medical Holding Corp (ICU) - Friday, Jul 25, 2025

United States

SeaStar Medical Holding Corporation operates as a holding company. The Company, through its subsidiaries, provides medical devices to prevent respiratory distress syndrome, acute kidney injury, and many other health issues can result in a dangerous cytokine storm. SeaStar Medical Holding serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00